M
Malgorzata Krupa
Researcher at Flinders University
Publications - 7
Citations - 134
Malgorzata Krupa is an academic researcher from Flinders University. The author has contributed to research in topics: Multiple sclerosis & Gene. The author has an hindex of 5, co-authored 7 publications receiving 111 citations. Previous affiliations of Malgorzata Krupa include Flinders Medical Centre.
Papers
More filters
Journal ArticleDOI
The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease
Grant P Parnell,Prudence N. Gatt,Malgorzata Krupa,Dorothee Nickles,Fiona C. McKay,Stephen D. Schibeci,Marcel Batten,Sergio E. Baranzini,Andrew P.D. Henderson,Michael Barnett,Mark Slee,Steve Vucic,Graeme J. Stewart,David R. Booth +13 more
TL;DR: Optimal response to therapy might be indicated by normalization of expression of these genes in blood, after a marked over-representation of transcription factors controlling differentiation of T, B, myeloid and NK cells among the 110 MS genes now known to be associated with multiple sclerosis.
Journal ArticleDOI
Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study
Sunil Mahurkar,Max Moldovan,Max Moldovan,Vijayaprakash Suppiah,Melissa Sorosina,Ferdinando Clarelli,Giuseppe Liberatore,Sunny Malhotra,Xavier Montalban,Alfredo Antigüedad,Malgorzata Krupa,Vilija Jokubaitis,Fiona C. McKay,Prudence N. Gatt,Marzena J. Fabis-Pedrini,Vittorio Martinelli,G. Comi,Jeannette Lechner-Scott,Allan G. Kermode,Allan G. Kermode,Mark Slee,Bruce V. Taylor,Koen Vandenbroeck,Koen Vandenbroeck,Manuel Comabella,Filippo Martinelli Boneschi,C King +26 more
TL;DR: To identify IFN-β treatment response genetic marker(s) by performing a two-stage genome-wide association study (GWAS), eight single-nucleotide polymorphisms (SNP) showed evidence of association with treatment response.
Journal ArticleDOI
A novel mitochondrial DNA deletion producing progressive external ophthalmoplegia associated with multiple sclerosis
Mark Slee,Mark Slee,James Finkemeyer,Malgorzata Krupa,Ravinarayan Raghupathi,J. Gardner,Peter C. Blumbergs,Mark J. Agzarian,Dominic Thyagarajan,Dominic Thyagarajan +9 more
TL;DR: The deletion resulted in significant respiratory chain deficiency in muscle and blood and abnormalities of the platelet mitochondrial membrane potential, and cerebrospinal fluid analysis, magnetic resonance spectroscopy and MRI features suggested inflammatory central nervous system demyelination rather than a primary respiratory chain disorder.
Journal ArticleDOI
Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season
Grant P Parnell,Prudence N. Gatt,Fiona C. McKay,Stephen D. Schibeci,Malgorzata Krupa,Joseph E. Powell,Peter M. Visscher,Grant W. Montgomery,Jeannette Lechner-Scott,Simon Broadley,Christopher Liddle,Mark Slee,Steve Vucic,Graeme J. Stewart,David R. Booth +14 more
TL;DR: In this article, the effect of interferon beta (IFNB) therapy on expression was evaluated and rationalized to a single marker, ribosomal protein S6 (RPS6).
Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season | NOVA. The University of Newcastle's Digital Repository
Grant P Parnell,Prudence N. Gatt,Christopher Liddle,Mark Slee,Steve Vucic,Graeme J. Stewart,David R. Booth,Fiona C. McKay,Stephen D. Schibeci,Malgorzata Krupa,Joseph E. Powell,Peter M. Visscher,Grant W. Montgomery,Jeannette Lechner-Scott,Simon A. Broadley +14 more
TL;DR: Data support investigation of RPS6 as a potential therapeutic target and candidate biomarker for measuring clinical response to IFNB and other MS therapies, and of MS disease heterogeneity.